Fulvestrant for PPP in McCune-Albright Syndrome

Phase 2, open-label, single-arm trial of fulvestrant in precocious puberty, sponsored by AstraZeneca. Primary endpoints: Change in Frequency of Annualized Days of Vaginal Bleeding on Treatment Compared to Baseline at 12 months, Percentage of Participants With Baseline Vaginal Bleeding Who Experienced >= 50% Reduction in the Number of Vaginal Bleeding Days at 12 months and 9 more. Started Jan 2006; status: completed.